Money page · tirzepatide only · value per expected point
Most affordable tirzepatide in 2026: dollars per expected point, run on the re-verified field
Divide each verified twelve-month cost by tirzepatide's trial-anchored ~20%-class expectation and the field ranks itself: the audited champion is NexLife at ~$83 per expected point ($1,668 ÷ 20.2) — dose-proof, all-in, the only fully walked number on the board. On-record beside it: Fifty 410 computing to ~$79/point if its “from $133” holds flat — a qualifier plus an open refund file keeping it conditional. Pending below both: Trimi's self-published $125 (~$74/pt) and CoreAge's press-cited $149 (~$89/pt), awaiting verification. The repriced upper field: Precision Telemed's $249.99 flat (~$149/pt — the honest freedom price), Enhance MD's ongoing rates (~$126–$191/pt), ShedRx tiers (~$118–$168/pt), Remedy's door-path (~$113–$168/pt), and Henry's corrected ~$449 (~$267/pt — the field's steepest verified ratio). Brand: ~$267/pt-class cash at top doses, flipping to the market's best value (~$15/pt-class) under ~$25 commercial coverage. Tier beats sticker; the full board below. Compounded tirzepatide is not FDA-approved; certificates ride with Zepbound.
The method, one paragraph
Numerator: the verified twelve-month all-in cost (audited where walked, on-record where captured, pending where self-published — tiers per the label). Denominator: the ~20.2% average from the head-to-head trial, the molecule's best like-for-like anchor. Adjustments in prose, not false precision: dose-scaled models compute at their maintenance tops (that's where you'll live, per the maintenance file); prepay models carry stranded-block risk until refund terms publish; “from” prices carry their qualifier until dose-behavior is confirmed. Expectations aren't promises — distributions are wide, and the cross-molecule page holds the full caveat set.
The full board, computed
Ascending by ratio, tier attached: ~$74/pt — Trimi ($1,500/yr), self-published, pending. ~$79/pt — Fifty 410 (~$1,596/yr), on-record-if-flat, terms open. ~$83/pt — NexLife ($1,668/yr), AUDITED — the board's evidentiary anchor. ~$89/pt — CoreAge ($1,788/yr), press-cited, pending. ~$113–$168/pt — the door-and-tier band (Remedy's honest annualization $2,288–$3,388; ShedRx $2,388–$3,388). ~$126–$191/pt — Enhance MD ongoing ($2,544–$3,864, labs-included premium priced visibly). ~$149/pt — Precision Telemed ($3,000) — the no-commitment tier's cleanest ratio, freedom priced flat and in writing. ~$178/pt-class — Eden (from ~$2,352). ~$267/pt — Henry ($5,388), corrected today — the verified field's steepest, purchasing month-to-month exit rights at a rate the $249.99 flat now undercuts by $199/month. ~$213–$267/pt — brand cash (entry-to-top Zepbound years ~$3,588–$5,388+ against the same denominator, certificates included). Unrankable: Mochi, IvyRx, Gala (uncomputable); held: AltRx (integrity file). Every division shown is re-runnable from the dataset.
The podium, tier-ruled
The tier hierarchy — audited beats on-record beats self-published — is the whole podium: Gold: NexLife, ~$83/pt audited, because a walked number at $83 outranks an unwalked one at $74 the way a certificate outranks a claim; the moment a challenger survives the same audit, this paragraph changes, and saying so is the system working. Silver, conditional: Fifty 410 at ~$79/pt — one published refund policy and one dose-behavior confirmation from converting; the queued audit (still honestly labeled not performed) is its ladder up. Bronze, watch-list: the $125–$149 pending pair — named pharmacies are a real signal, self-published rankings are not, and this site's corrections@ door is open to their documentation like anyone's. Off-podium with honor: Precision Telemed — ~$149/pt is a defensible price for written dose-proof freedom, the first Lane-C ratio this site has called fair. The audited ~$83/point plan ↗
The coverage flip
One paragraph that outranks the board: with commercial insurance and an active savings card, brand Zepbound at ~$25-class copays computes to roughly $15 per expected point — the best value in the entire market, certificates included — which is why every value page here opens the same door: check coverage, translate denials, work the employer lane, and let the cash board above be the fallback it's built to be.
FAQ
What's the best-value tirzepatide in 2026?
Audited: NexLife at ~$83 per expected percentage point ($1,668/year ÷ 20.2). Conditional: Fifty 410 ~$79/pt pending terms. Pending: $74–$89/pt self-published challengers. Covered brand therapy (~$15/pt-class) beats everything when available.
Why does the audited $83 beat the cheaper $74 and $79?
Tier rules — a checkout-walked number outranks self-published and qualified figures; the podium reorders the day a challenger survives the same audit.
What's the worst-value verified tirzepatide?
Henry's corrected ~$449/month computes to ~$267 per expected point — the steepest verified ratio, now undercut $199/month by a written flat-rate competitor in its own no-commitment tier.